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Intracellular pH and Na/H1 antiport activity of cultured skin libro-
blasts from diabetics. Increased leucocyte Na/H antiport activity has
previously been demonstrated in both hypertensive subjects and Type
I diabetic patients with nephropathy and may indicate a predisposition
to hypertension in such diabetic patients. We have studied intracellular
pH and Na/H antiport activity in cultured skin fibroblasts from
diabetic patients with and without nephropathy, together with non-
diabetic controls to assess if such differences persisted in cultured cells.
Fibroblasts from diabetic patients with nephropathy were significantly
more alkaline [median (range): 6.90 (6.82 to 7.07)] compared to both
normoalbuminuric diabetic patients [6.81 (6.75 to 6.89)] or normal
controls [6.82 (6.77 to 6.93)] (P < 0.001 for both). This was associated
with a raised Na /H antiport activity in cells from patients with
nephropathy when intracellular pH (pH) was clamped to pH 6.5,
without any differences in the maximal transport capacity of the
antiport at pH 6.2. Using both intracellular pH and Na/H antiport
activity at pH 6.5, patients with nephropathy were separated from
uncomplicated subjects with a sensitivity of 92% and a specificity of
100%. In conclusion, the raised Na/U antiport activity in cells from
patients with diabetic nephropathy persists despite passaging in vitro,
thus indicating a heritable component, and results mainly from an
increased apparent affinity of the antiport for intracellular H.
Renal disease develops in up to 35% ofpatients with Type I
diabetes and is a major cause of mortality and morbidity [I]. It
remains unclear as to why only some patients develop this
complication. Blood glucose control contributes to it but does
not account for the entirety of the phenomenon [2], and other
factors have been implicated in its pathogenesis. They include a
family history of nephropathy [31, parental hypertension [4] or
a predisposition to hypertension and its complications, as
indicated by elevated red cell Li/Na countertransport [5,6].
An increased Na/H antiport activity had been reported in
leukocytes from humans with both essential hypertension [7]
and diabetic nephropathy [8, 9], and in skeletal and vascular
smooth muscle cells from spontaneously hypertensive rats [10,
11]. Recent data from our group have also demonstrated an
increased amiloride-sensitjve Na influx (and enhanced 3H-
thymidine incorporation) in cultured skin fibroblasts from Type
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I diabetic patients with proteinuria [12]. This increased Na
influx was due to an increased maximal transport capacity for
extracellular Na in the patients with nephropathy. Thus, the
changes in ion transport may be present in a variety of cell types
and in diabetic nephropathy [8, 9, 12], and the increased
Na/H4 antiport activity was independent of glycemic level or
blood pressure control.
In the present investigation, we have examined intracellular
pH (pH1) and NafH antiport activity of cultured skin fibro-
blasts from diabetic patients with and without nephropathy, and
made a detailed study of the effect of intracellular H * on
transport rates. Using a double ionophore pH1 clamping tech-
nique, the maximal transport capacity and apparent affinity of
the antiport for internal H was determined. Lastly, a discrim-
inant function was sought for separation of patients into those
with and without nephropathy.
Methods
Materials
2,7' Bis-(carboxyethyl)-5,6-carboxyfluorescein acetoxymeth-
yl ester (BCECF-AM), non-esterified fatty acid free bovine
serum albumin (BSA), glutamine, nigericin, monensin and
tissue culture medium TC199 were from Sigma Chemicals
Ltd., Poole, Dorset, United Kingdom. Dulbecco's modified
Eagle's medium (DMEM), fetal calf serum (FCS), penicillin and
streptomycin were obtained from Flow Laboratories Ltd.
(Rickmansworth, UK). The TC199 was buffered with 15 mmol/
liter N-2-hydroxyethylpiperazine-N '-2-ethanesulfonic acid
(HEPES) to pH 7.4.
Patients and fibroblast cell culture
Skin biopsies were obtained from 12 normal healthy control
subjects, 10 normoalbuminuric Type I diabetic patients and 12
diabetic patients with nephropathy. Their clinical characteris-
tics are shown in Table 1. Nephropathy was defined as a median
albumin excretion rate of three overnight sterile urine collec-
tions greater than 70 .tgImin, in a patient with more than 10
years duration of Type 1 diabetes, and no heart failure or other
renal disease. Normoalbuminuric diabetic patients had a me-
dian albumin excretion rate consistently below 15 g/min and
were matched for age, duration of diabetes and body mass
index. Both control subjects and normoalbuminuric diabetic
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Table 1. Characteristics of the subjects studied
Number (males)
Age years
Body mass index kg m2
Duration of IDDM years
Insulin dose U/day
Systolic BP mm Hg
Diastolic BP mm Hg
Glycosylated Hb %
Urine albumin excretion pg/mm
Creatinine smoI/1iter
On anti-hypertensive therapy
Retinopathy
Absent
Background
Proliferative
IDDM patients with
nephropathy
12 (9)
37 [29—60
22.7 [19.5—27.2]
22.5 1 13—39]
48 [27—93]
130 [lIO_170]a
90 [68—95]"
8.7 [6.7—11.3]
356 [94—4951]"
120 [79—299]"
l0
IDDM patients without
nephropathy
10 (8)
40.5 [33—62]
22.9 [19.3—26.9]
26 [20—33]
44 [39—70]
133 [l20_165]a
80 [72—92]"
8.4 [7.5—10.2)
5.3 [0.7—12.0]
82 175—107]
8
Non-diabetic
controls
12 (8)
37.5 [23—65]
23.3 [21.7—29.7]
120 [100—145]
70 [60—91]
patients had a negative family history of hypertension. Blood
pressures were measured twice to the nearest 2 mm Hg on an
ordinary sphygmomanometer after 10 minutes of rest in the
supine position, and any patients on antihypertensive medica-
tion were recorded. The presence of retinopathy was deter-
mined by fundoscopy through dilated pupils and graded as
absent, background or proliferative retinopathy. Weight and
height were recorded, and blood taken for determination of
glycosylated hemoglobin (Corning gel electrophoresis, Ciba-
Corning, California, USA) and serum creatinine (Jaffé reaction
rate method, Hitachi autoanalyser, BCL, UK).
The DMEM was buffered with 25 mmol/liter NaHCO3 (pH
7.4 in 95% air, 5% C02) and contained 10% FCS, 5 mmol/Iiter
glucose, 1 mmol/liter glutamine, o5 lU/liter penicillin and 100
mg/liter streptomycin. Skin fibroblasts were grown in DMEM
and fed twice weekly. Cells were trypsinized when confluence
was achieved, After five to six passages, the cells were seeded
onto 9 x 22 mm coverslips, using about l0 cells per slip.
Measurements were made two days after seeding these cells,
without a period of serum withdrawal.
Measurement of intracellular pH and Na/H antiport
activity
The confluent cells on cover slips were loaded with the pH
fluorophore BCECF in the ester form (10 mol/liter in TC199)
at 37°C for '/2 hour. The slips were then washed three times with
the TC199 (containing 0.1% dialyzed FCS) and left in this
medium for at least '/2 hour at room temperature before any
measurements were made, to ensure intracellular de-esterifica-
tion of the BCECF-AM.
Resting intracellular pH (pH,) was measured by clamping the
cover slip rigidly in specially constructed I x 1 cm cuvettes, so
that the cover slip was at an angle of 60° to the incident light.
Changes in the position of the cuvette could lead to spurious
changes in the fluorescence ratios, and so, care was taken to
ensure that no movement of the cuvette or cover slip took place
once measurements were commenced.
The cuvette was warmed to 37°C in a thermostatted holder,
and pH was determined in HEPES buffered saline (in mmol/
liter, NaCI 140, KCI 5, CaCl2 1.8, MgSO4 0.8, glucose 5,
HEPES 15, BSA 1 g/liter, pH 7.4 at 37°C). pH, fell gradually on
introduction of warmed HEPES buffered saline, reaching a
steady state after 10 minutes. This value is the one that we
reported. The two excitation wavelengths were set at 500 and
439 nm (slit widths 5 nm) with emission at 530 nm (slit width 5
nm) in a single photon counting dual excitation fluorometer
(Photon Technology International Deltascan, South Brunswick,
New Jersey, USA). Autofluorescence was subtracted from
fluorescence readings before calculation of 500/439 ratios. The
500/439 ratios were subsequently converted to pH values by
construction of a calibration curve for every cover slip studied
to prevent bias from potential differences in position of the
cover slip. pH, was clamped to 7.8, 7.6, 7.0 and 6.5 or 6.2 in
isotonic KCI buffers (in mmol/liter), KCI 140, CaCI2 1.8, MgSO4
0.8, glucose 5, HEPES 15, with 5 imol/liter nigericin and 5
mol/liter monensin) as previously described [7—9, 11]. Fluo-
rescence ratios F (500/439 nm) were converted to pH values by
the following relationship obtained from the calibration proce-
dure [8, 9, 111:
/B xF=A+ I
+ 10(pH-pK)
where A and B are constants unique to each cover slip, pK is
the pK of the intracellular BCECF.
After this calibration procedure, the ionophores were re-
moved from the cells by incubation for two minutes in an
identical KCI buffer (pH 6.5 or 6.2) without the ionophores but
containing 1 g/liter BSA. The intracellular buffering capacity
was then determined at pH1 using NH4CI (10 mmol/l at pH, 6.5
and 50 mmol/liter at pH, 6.2), in the KCI buffer containing BSA.
Isotonicity was maintained by the sum of NH4 and K ions
being 140 mmol/liter. After a plateau was achieved, cells were
reclamped to pH, 6.5 or 6.2 using the double ionophore tech-
nique described above, with subsequent washing in KCI buffer
containing BSA. The efflux of H purely from the internal to
external pH (pH) gradient (pHi 6.5 or 6.2, PHe 7.4) was then
measured by changing the KCI buffer to one containing 140
2
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Results are medians [ranges].
"P < 0.05 compared to non-diabetic control subjects (Mann-Whitney U test)
h P < 0.001 compared to diabetic patients without albuminuria (Mann-Whitney U test)
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mmollliter N-methyl-D-glucamine chloride (NMG Cl) to re-
place the KCI. The slope of this passive H effiux is indepen-
dent of Na/H4 antiport activity, and was not different from the
efflux determined using HEPES buffered saline, pH 7.4 con-
taining 10 mol/liter ethyl-isopropyl amiloride [11]. Use of
NMG Cl to determine the passive H efflux enabled the total
W effiux to be measured in the same coverslip subsequently,
whereas if amiloride had been employed to determine passive
H efflux, subsequent measurement of total H efflux would
have been impaired. After this measurement, the same cover-
slip was then clamped back to the original pH1, the ionophores
scavenged with BSA, and then total H effiux measured on
addition of external HEPES buffered saline, pH,, 7.4. The rate
of change of pH1 due to the Na/H antiport is the difference
between the slope of the efflux measured in HEPES buffered
saline and that measured in buffered NMG Cl. In most cases,
the passive H efflux comprised of under 10% of the total H
efflux, indicating that in HEPES buffered saline, the majority of
the pH1 recovery was attributed to Na/H antiport activity.
All slopes had Pearson correlation coefficients exceeding 0.99,
and were obtained from 90 readings taken over 18 seconds from
addition of the solutions. All measurements were in triplicate.
These rates of change of pH1 (in pH U/mm) were converted to
units of flux rate (in mmol/liter/min) after multiplying by the
intrinsic buffering capacity (in mmol/liter/pH unit) determined
earlier on the same cover slip. The values of pH1 of 6.5 and 6.2
were chosen since at 6.2, the Na/H antiport activity is
virtually at its maximal transport rate, and the apparent Km for
intracellular H is at about 6.5 [11]. At pH1 values less than 6.2,
the relationship between pH and fluorescence emission ratio of
BCECF becomes flatter, so that only large changes in pH leads
to changes in the ratio. This would result in relatively larger
errors in determination of effiux rates and buffering capacity
below pH 6.2.
The measurements of pH1 and Na/H antiport activity in the
fibroblasts were done blind (JED, LLN), so that the origin of
the cells was not known till all the data were collected.
Statistics
Data were analyzed using an Oxstat statistics package (Mi-
crosoft Corporation, Reading, Berks, UK) or a Statsgraphics
package. Medians and ranges are reported, and comparisons
were by Kruskal-Wallis analysis of variance and the Mann-
Whitney U test. Two-tailed P values less than 0.05 were taken
as significant. Spearman correlation coefficients were also cal-
culated and discriminant analysis was performed on a Stats-
graphics package.
Results
Systolic and diastolic blood pressures were higher in both
diabetic groups compared to controls (P <0.05, Table 1). There
was no difference in blood pressures between the two diabetic
groups but this may have been due to anti-hypertensive therapy
in the nephropathy group. The two diabetic groups were treated
with similar doses of insulin daily and at the time of skin biopsy,
had similar glycosylated haemoglobin (HBAIC) levels (Table 1).
Serum creatinine levels were higher in the group with diabetic
nephropathy ('cable I).
The determination of intracellular pH (pHj), calibration of
pH1 using the double ionophore method described earlier, the
change in pH1 resulting from NH4CI (for measurement of the
buffering capacity), and the subsequent determination of H
efflux into NMG Cl and NaCI buffers on a single cover slip are
illustrated in Figure 1, with the response to addition of NaC1
illustrated in diabetic subjects with and without nephropathy
and a normal control subject. Differences in pH, (measured in
HEPES buffered saline) were found between the three groups
of subjects (P < 0.0008). In the cultured skin fibroblasts, the
pH1 was significantly higher in the cells from patients with
diabetic nephropathy than both the normal controls and dia-
betic subjects without nephropathy (P < 0.001 for both, Table
2, Fig. 2). However, in the presence of 24 mmol/liter NaHCO3
(equilibrated with 5% C02), the pH1 was very similar in diabetic
subjects with and without nephropathy.
In nominally HCO free HEPES buffered solutions, there
were no differences in the intrinsic buffering capacity between
all the groups at both the pH, employed in the pH clamp
technique, namely 6.5 and 6.2 (Table 2). When the pH1 of cells
was clamped to 6.5, the rate of recovery of pH1 dependent on
Na/H4 antiport activity (that is, the difference between the
total rate in NaCl buffer and the passive rate in NMG Cl buffer)
was different between the three groups (P < 0.002), being
significantly higher in the subjects with diabetic nephropathy
than both normal controls and normoalbuminuric diabetic pa-
tients (P < 0.001 for controls, P < 0.005 for the normoalbumin-
uric diabetic patients, Table 2). Since H effiux rate is the
product of this rate of recovery of pH1 and buffering capacity,
the W efflux rate at pH1 6.5 was also significantly different
between the groups (P < 0.0005), being raised in the group of
diabetic subjects with nephropathy (P < 0.001 for controls, P <
0.002 for the normoalbuminuric diabetic patients, Table 2, Fig.
3).
There were no significant differences between the rates of
change of pH1 or the H effiux rates due to passive H effiux
mechanisms between the different groups of subjects.
The maximal transport capacity (Vmax) of the Na'/H an-
tiport activity occurs at pH1 in the range 6 to 6.2. When pH1 was
clamped to this level, H efflux rates and rate of change of pH1
attributable to the Na/H antiport were very similar in the
three groups of subjects studied (Table 2, Fig. 4). No significant
correlations were found between blood pressure, duration of
diabetes, age or HbAIC levels and any of the pH, or Na/H
antiport activity measurements.
The intrinsic buffering capacity was higher at pH1 6.2 than
6.5, in all the groups studied (P < 0.001, Table 2), resembling
the findings in leukocytes [8]. As expected, H4 effiux rates were
higher at pH1 6.2 than pH, 6.5 (Table 2).
As there was some overlap between both pH, values and
Na4/H antiport activity at pH, 6.5 of the group with diabetic
nephropathy and those subjects without nephropathy, we
sought to define a discriminant function that may help differen-
tiate between membership in the nephropathy group from the
other group of uncomplicated subjects. A significant negative
correlation was noted in the normal controls between resting
pH, and Na/H antiport activity at pH, 6.5 (r = —0.62, P <
0.03) and in the normoalbuminuric diabetic group (r
—0.89,
P < 0.001, Fig. 5). Although this correlation was not seen in the
nephropathy group, this was due to an outlier, and r was —0.54
if this subject was excluded. Thus, a lower resting pH1 is
associated with a higher Na/H antiport activity (at pH, 6.5,
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Fig. 1. A typical experiment for measurement
of pH, and Na/H antiport activity on
fibroblasts cultured on cover slips. The time
scale is only relative, as the record was
stopped for periods varying from two to five
minutes at the arrows. Resting pH was
determined in HEPES buffered NaCl after
warming the cells at 37°C for 10 minutes. The
cells were then bathed with KCI media
containing nigericin and monensin to clamp
the pH1 at 7.6, 7.0 and 6,2 or 6.5 (an
equilibration period of 5 mm occurred at each
change of solution, to ensure fluorescence
ratios had stabilized from the change in pH).
After removing the ionophores with BSA,
introduction of NH4CI enabled buffering
capacity to be determined. The record was
stopped when a plateau was achieved, and
cells were reclamped with KCI/ionophore
buffer for two minutes (to pH, 6.5 in this
experiment) with another two minute wash in
KCI buffer with BSA (not illustrated).
Introduction of NMG Cl enabled
measurement of passive H effiux, and after
another period of reclamping to pH1 6.5, effiux
was finally determined in HEPES buffered
NaCI. Correlation coefficients were
determined for the first 18 seconds after
introduction of NMG Cl or NaCI to measure
the rate of change of intracellular pH with
time. The rates of change of pH1 after addition
of NaCI are shown for a fibroblast culture
from a patient with nephropathy (IDDM
nephropathy), a diabetic subject without
nephropathy (IDDM) and a normal non-
diabetic control subject.
when max has not been reached). This relationship between
pH1 and Na/H antiport activity (pH, 6.5) in the group of
patients with nephropathy is shifted to the right compared to the
normal controls and diabetic subjects without nephropathy.
The discriminant function that separates the majority of these
nephropathy patients from both controls and diabetic patients
without nephropathy is as follows:
Na ÷ /H + antiport efflux rate (pH1 6.5)
= ( — 34.305 x pHj + 240.516
(chi square 41.82, P <0.00001).
Using this function, the sensitivity of classification of those with
nephropathy was 92%, with a specificity of 100%.
Discussion
Using skin fibroblasts from diabetic patients with and without
nephropathy, the resting pH, is raised in those with nephrop-
athy. As our studies were conducted in HCO free media, pH1
regulation is mainly attributed to Na /H antiport activity.
However, in the presence of 24 mmol/liter HCO (5% C02),
there was no significant difference between the resting pH1 of
patients with and without nephropathy. Thus, although
Na/H antiport activity differences are found in patients with
nephropathy, the presence of additional pH, regulatory mech-
anisms when HCO is present in a true physiological situation
(such as Na dependent Cl/HCO exchange, which is stimu-
lated by intracellular acidosis, and Na independent Cl/HCO
exchange, which is stimulated by intracellular alkalosis) [13—151
led to a correction of any changes in pH, due to alteration in
Na/H antiport activity. In order to exclude the effects of
Cl/HCO exchange so that the kinetics of the Na/H an-
tiport could be studied in isolation, we performed H effiux
studies in the nominal absence of HCO (HEPES buffered
media).
Using the technique of pH1 clamping, Na/H antiport
activity was raised in the group with nephropathy at pH, 6.5.
Since the antiport activity at pH1 6.2 was similar between the
groups, the Vmax of the antiport was not different between
groups. Our findings could therefore be interpreted as an
increased apparent affinity of the antiport for intracellular H in
the group with nephropathy, resulting in a shift in the set point
for regulation of pH, in an alkaline direction. This alkaline shift
in pH1 has been previously described in leucocytes from pa-
tients with diabetic nephropathy [8, 91, although the increased
Na/H antiport activity in leukocytes was mainly from an
increased It is uncertain at present whether these differ-
ences between different types of cell could result from the serial
passaging to which fibroblasts were subjected. The differences
present in the fibroblasts from nephropathy patients have
therefore persisted despite culturing in vivo in standard condi-
tions (with the same growth medium, serum and glucose
concentrations) and may represent a genetic difference between
the groups. The leukocytes were studied within hours of
venesection, and would have been exposed to differences
Nigericin/KCI
calibration
Resting buffer ph
ph 7.6 7.0 6.5 NH4CL NMGCI
1111 1
Nigericin/KCI
pH 6.5, then
BSA, pH 6.5
NaCI
Ii
BSA
'I,Ia-
ce
a)0
C
8.0-
7.5-
7.0-
6.5-
6.0-
IDDM+nephropathy
IDDM
Normal control
0 0.5 1.0 1.5 2.0 2.5
Time, minutes
3.0 3.5 4
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Table 2. Measurements performed on the skin fibroblasts of control subjects, diabetic patients with and without nephropathy
IDDM patients with
nephropathy
IDDM patients without
nephropathy
Non-diabetic
controls
Resting pH (in HEPES buffer) 6.90
[6.82—7.071
6.81
[6.75—6.89]
6.82
[6.77—6.93]
Resting pH (in HCO buffer) 7.03
[6.95—7.181
7.02
[6.95—7.12]
—
Measurements at pH1 6.5
Buffering capacity mmol/!iter/pH unit 16.6
[12.2—29.7]
14.6
[12.4—25.6]
16.1
[11.8—25.8]
dpH1/dt from passive H efflux 0 0.03 0
pH units/mm [0—0.06] [0—0.23] [0—0.15]
Passive H + efflux mmol/liter/min 0.1
[0—1.39]
0.42
[0—1.56]
0.1
[0—0.66]
dpH1/dt from Na/H antiport 0.49k'" 0.28 0.19
pH U/mm [0.21—0.75] [0.15—0.47] [0.05—0.521
Na/H antiport activity (pH1 6.5) 8.96a,4 4.17 3.20
mmol/liter/min [3.27—13.54] [2.66—5.85] [1.23—7.50]
Measurements at pH 6.2
Buffering capacity mmol/liter/pH unit 28.7
[17.7—36.9]
27.3
[18.7—36.8]
29.6
[16.5—44.8]
dpH1/dt from passive H efflux 0.11 0.10 0.08
pH U/mm [0—0.23] [0.02—0.25] [0—0.17]
Passive H efflux mmol/!iter/min 3.56
[0—5.83]
2.29
[0.67—4.37]
1.65
[0—6.05]
dpHjdt from Na/H antiport 0.62 0.56 0.68
pH U/mm [0.26—1.39] [0.28—1.16] [0.21—0.68]
Na/H antiport activity (pHi 6.2) 18.41 15.71 20.43
mmol/liter/min [10.76—28.08] [6.81—33.62]
-
[7.29—32.70]
Results are medians [ranges]. Both rates of change of intracellular pH (dpH1/dt) due to Na/H exchange and passive mechanisms measured in
the absence of HCO are shown.
a P < 0.001 compared to normal controls (Mann-Whitney U test)
b P < 0.001 compared to diabetic patients without nephropathy
P < 0.002 compared to diabetic patients without nephropathy
d P < 0.005 compared to diabetic patients without nephropathy
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Fig. 2. Resting intracellular pH measurements for normal controls,
diabetic patients with and without nephropathy. Medians are indicated
by the bar.
present in the plasma of the various subjects. Even if it is
postulated that the effects of previous hyperglycemia could
persist in culture, this cannot explain the difference between the
diabetic groups with and without nephropathy, for the cells
were derived from patients with similar levels of glycemic
control.
We studied cells that had been passaged five to six times to
ensure that the direct effects of antihypertensive treatment
0
0
00
0
9j0
4...
.
4
15
10-
5-
0
Controls IDDM IDDM nephropathy
Fig. 3. Fibroblast Na/H antiport activity at pH 6.5 for normal
controls (0), and diabetic patients with (+) and without nephropathy
(a). Medians are indicated by the bar.
(which had been employed in most of the patients with nephrop-
athy and only one of the diabetic patients without nephropathy)
on Na /H antiport activity were minimized. However, a
persistent effect of medication on antiport numbers, although
unlikely, cannot be totally excluded.
Our group has also demonstrated that the Vmax of the
Na/H antiport for extracellular Na was increased in skin
fibroblasts from patients with diabetic nephropathy compared
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Controls IDDM IDDM nephropathy
Fig. 4. Fibroblasi Na'7H antiport activity at pH1 6.2 for normal
controls (0), diabetic patients (•) with and without nephropathy (A).
Medians are indicated by the bar.
to controls and diabetic patients without nephropathy [12]. In
these experiments, an ammonium chloride prepulse method
was used to achieve intracellular acidification, leading to a fall
in pH1 to about 6.4, but intracellular Na was not directly
manipulated. As a result, changes in Na influx documented
could have been due not only to changes in Na/H antiport
activity, but also to alterations in the transcellular Na gradi-
ent. Furthermore, pH1 was not measured directly in the cells in
which Na influx was studied, and differences of influx could
have resulted from differences in the pH1 achieved using the
NH4CI prepulse. In the present study, the extracellular Na of
140 mmol/liter would have saturated the external site of the
Na /H antiport, and the differences in flux were demonstrated
only at pH1 of 6.5 and not 6.2. Furthermore, the intracellular
Na was manipulated by the double ionophore technique to
around zero, with intracellular K set at 140 mmol/liter [7—9,
11], so that any differences in the H effiux rate would be
directly due to changes in Na/H antiport activity and not
changes in transcellular ionic gradients. It is likely that the
changes in Vmax for Na externally, which have been previ-
ously reported [12], are secondary to the increased apparent
affinity for H on the internal site of the antiport, leading to an
alkaline shift of the activation curve for intracellular H . Thus,
in conjunction with the previous study [121, the 1/H'
antiport from cells of patients with diabetic nephropathy is
characterized by a raised transport capacity for external Na
and a raised apparent affinity for internal H.
The negative correlation between pH1 and Na/H antiport
activity at pH1 6.5 may imply that the intracellular pH may
regulate the apparent affinity of the antiport for intracellular
H, so that a more acid pH1 would lead to a higher affinity for
H leading to more efflux. However, no relationship with
the Vmax of the Na/H antiport at 6.2 was found. This is of
teleological advantage for metabolizing cells constantly produc-
ing H , where many cytosolic reactions are pH dependent.
Changes in the Vmax may not regulate pH1 as effectively as
changes in apparent affinity of the antiport, in the face of an
intracellular acid load. Regarding the relationship between pH1
and Na/H antiport activity (pH1 6.5), there was no difference
12-
0-
6.7 6.8 6.9 7.0 7.1
Intracellular pH
Fig. 5. The relationship between intracellular pH and NaJH an-
tiport activity (at pH1 6.5) in normal controls (0), diabetic patients
without nephropathy (A) and with nephropathy (•). The discriminant
function described in the text is illustrated by the solid line.
between normal controls and normoalbuminuric diabetic pa-
tients, but the relationship for the nephropathy patients is
shifted in an alkaline direction. The cause for this alkaline shift
and that of the resting pH1 is at present unknown. However,
activation of the Nat7H antiport by growth factors, especially
involving phosphorylation of the protein, leads to an alkaline
shift of the set point [16]. Preliminary evidence for the putative
role of protein kinases in the activation of the Na/H antiport
in diabetic nephropathy already exists for leukocytes [9], but
remains to be investigated in cultured fibroblasts. Serum leads
to a larger increase in pH1 and 3H-thymidine incorporation in
fibroblasts from patients with diabetic nephropathy than in
normal controls and diabetic patients without nephropathy [12],
although the factor(s) responsible for this phenomenon are not
known at present.
Individually, measurements of pH, or the Na/H4 antiport
activity at pH 6.5 cannot be used to define membership of the
group of diabetic patients with nephropathy due to the substan-
tial overlap (of about a third) between this group and the others.
However, using the relation between pH1 and Na/H antiport
activity (at pH1 6.5), a discriminant function is described
enabling the membership of the nephropathy group to be
predicted specifically with a sensitivity of over 90%. It remains
to be demonstrated that this function pertains for larger popu-
lations and if so, its predictive power for future nephropathy in
Type I diabetes could be tested prospectively.
In conclusion, we have demonstrated that pH1 is shifted in an
alkaline direction in cultured fibroblasts from patients with
diabetic nephropathy, and that this resulted from a raised
Na/H antiport activity (at pH1 6.5), resulting from an in-
creased affinity of the antiport for internal Ht It was possible
to predict membership of the nephropathy group by a discrim-
inant function involving resting pH1 and Na/H antiport
activity. As the structure of the antiport is now known [16],
studies on the mechanism of activation of this protein in
diabetic nephropathy may now be possible, such as changes in
the level of antiport protein or its phosphorylation. Future work
should determine if these findings could help to prospectively
identify diabetic patients at risk of nephropathy.
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